“The monoclonal antibody UB-421 “demonstrated unprecedented and sustained” virologic suppression in the absence of ART among people with HIV during a nonrandomized, open-label, phase 2 clinical study, according to findings published today by The New England Journal of Medicine.”
For more, click here.